104846-62-0

Usage

Uses

Used in Pharmaceutical Industry:
tert-Butyl-dimethyl-(4-methylene-3-2-[7a-methyl-1-(1,4,5-trimethyl-hex-2-enyl)-octahydro-inden-4-ylidene]-ethylidene-cyclohexyloxy)-silane is used as an intermediate in the synthesis of various pharmaceutical compounds. Its unique molecular structure allows it to be a key component in the production of drugs with specific therapeutic properties.
Used in Chemical Synthesis:
In the field of chemical synthesis, tert-Butyl-dimethyl-(4-methylene-3-2-[7a-methyl-1-(1,4,5-trimethyl-hex-2-enyl)-octahydro-inden-4-ylidene]-ethylidene-cyclohexyloxy)-silane serves as a versatile building block for the creation of new compounds with potential applications in various industries. Its reactivity and stability make it a valuable asset in the development of novel chemical products.
Used in Research and Development:
Due to its unique structure and properties, tert-Butyl-dimethyl-(4-methylene-3-2-[7a-methyl-1-(1,4,5-trimethyl-hex-2-enyl)-octahydro-inden-4-ylidene]-ethylidene-cyclohexyloxy)-silane is used in research and development to explore its potential applications and to gain a deeper understanding of its chemical behavior. This knowledge can lead to the discovery of new uses and advancements in various fields.
Used in Impurity Control:
As an impurity of Vitamin D2 (V676040), a synthetic form of Vitamin D, tert-Butyl-dimethyl-(4-methylene-3-2-[7a-methyl-1-(1,4,5-trimethyl-hex-2-enyl)-octahydro-inden-4-ylidene]-ethylidene-cyclohexyloxy)-silane plays a role in the quality control and purity assessment of Vitamin D2 products. Its presence can be monitored and controlled to ensure the safety and efficacy of the final product.
Used in Synthesis of (7Z)-Calcipotriene:
tert-Butyl-dimethyl-(4-methylene-3-2-[7a-methyl-1-(1,4,5-trimethyl-hex-2-enyl)-octahydro-inden-4-ylidene]-ethylidene-cyclohexyloxy)-silane is also an intermediate in the synthesis of (7Z)-Calcipotriene (C144225), an isomeric impurity of Calcipotriene (1442000), a vitamin D3 analogue with low calcemic activity. Its involvement in this process highlights its importance in the production of pharmaceutical compounds with specific therapeutic properties.

InChI:InChI=1/C34H58OSi/c1-24(2)25(3)14-15-27(5)31-20-21-32-28(13-12-22-34(31,32)9)17-18-29-23-30(19-16-26(29)4)35-36(10,11)33(6,7)8/h14-15,17-18,24-25,27,30-32H,4,12-13,16,19-23H2,1-3,5-11H3/b15-14+,28-17+,29-18-/t25-,27+,30-,31+,32?,34+/m0/s1

Upstream product

• 50-14-6 Calciferol 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 51744-66-2 3β-hydroxy-9,10-secoergosta-5(E),7(E),10(19),22(E)-tetraene 
• 50-14-6 (S)-4-Methylene-3-[2-[(1R,3aS)-7a-methyl-1-((E)-(1R,4R)-1,4,5-trimethyl-hex-2-enyl)-octahydro-inden-(4E)-ylidene]-eth-(E)-ylidene]-cyclohexanol 
• 87407-73-6 (S)-3-[(1R,3aS)-7a-Methyl-1-((E)-(1R,4R)-1,4,5-trimethyl-hex-2-enyl)-octahydro-inden-(4E)-ylidenemethyl]-2,2-dioxo-2,3,4,5,6,7-hexahydro-1H-2λ⁶-benzo[c]thiophen-5-ol 
• 50-14-6 ergocalciferol 
• 247900-07-8 (7Z)-Vitamin D₂ 
• 87680-65-7 (S)-3-[(1R,3aS,7aR)-7a-Methyl-1-((E)-(1R,4R)-1,4,5-trimethyl-hex-2-enyl)-octahydro-inden-(4E)-ylidenemethyl]-2,2-dioxo-2,3,4,5,6,7-hexahydro-1H-2λ⁶-benzo[c]thiophen-5-ol 
• 170081-43-3 SO2-adduct of 3(S)-<(tert-butyldimethylsilyl)oxy>-9,10-secoergosta-5,7(E),10(19),22(E)-tetraene 
• 87417-26-3 (3S,6S)-(tert-butyldimethylsilyloxy)-9,10-seco-ergosta-5,7(E),10⁽¹⁹⁾,22(E)-tetraene SO₂-adduct 
• 87417-26-3 (3S,6R)-(tert-butyldimethylsilyloxy)-9,10-seco-ergosta-5,7(E),10⁽¹⁹⁾,22(E)-tetraene SO₂ adduct 

Downstream Products

• 87407-51-0 C₂₈H₄₈O₂Si 
• 228113-80-2 C₂₈H₄₈O₂Si 
• 87407-53-2 22-hydroxyhomopregnacalciferol 
• 115540-27-7 1(S),3(R)-3-(tert-butyldimethylsilyl)-9,10-secoergosta-5(E),7(E),10⁽¹⁹⁾,22(E)-tetraene-1-ol 
• 112670-78-7 (R)-5-(tert-Butyl-dimethyl-silanyloxy)-2-methylene-3-[2-[(1R,7aR)-7a-methyl-1-((E)-(1R,4R)-1,4,5-trimethyl-hex-2-enyl)-octahydro-inden-(4E)-ylidene]-eth-(E)-ylidene]-cyclohexanol 
• 112670-78-7 (1S,5R)-5-(tert-Butyl-dimethyl-silanyloxy)-2-methylene-3-[2-[(1R,3aS)-7a-methyl-1-((E)-(1R,4R)-1,4,5-trimethyl-hex-2-enyl)-octahydro-inden-(4E)-ylidene]-eth-(E)-ylidene]-cyclohexanol 
• 112670-78-7 (1S,5R)-5-(tert-Butyl-dimethyl-silanyloxy)-2-methylene-3-[2-[(R)-7a-methyl-1-((E)-(1R,4R)-1,4,5-trimethyl-hex-2-enyl)-octahydro-inden-(4E)-ylidene]-eth-(Z)-ylidene]-cyclohexanol 
• 54573-75-0 1α-hydroxyergocalciferol 
• 111594-58-2 (1R,7aR)-4-[2-[(3R,5R)-3,5-Bis-(tert-butyl-dimethyl-silanyloxy)-2-methylene-cyclohex-(E)-ylidene]-eth-(E)-ylidene]-7a-methyl-1-((E)-(1R,4R)-1,4,5-trimethyl-hex-2-enyl)-octahydro-indene 
• 111594-58-2 (1R,7aR)-4-[2-[(3S,5R)-3,5-Bis-(tert-butyl-dimethyl-silanyloxy)-2-methylene-cyclohex-(E)-ylidene]-eth-(E)-ylidene]-7a-methyl-1-((E)-(1R,4R)-1,4,5-trimethyl-hex-2-enyl)-octahydro-indene 
• 115540-28-8 (1R,3R)-bis(tert-butyldimethylsilyloxy)-1,10-seco-ergosta-5(E),7(E),10⁽¹⁹⁾,22(E)-tetraene 
• 115648-67-4 1(S),3(R)-bis<(tert-butyldimethylsilyl)oxy>-20(R)-formyl-9,10-secopregna-5(E),7(E),10(19)-triene 
• 112828-13-4 (5E,7E)-(1S,3R,20S)-1,3-bis<<(1,1-dimethylethyl)dimethylsilyl>oxy>-20-methyl-9,10-secopregna-5,7,10(19)-trien-21-al 
• 170081-46-6 (6S)- and (6R)-SO₂ adducts of 1(S),3(R)-bis(tert-butyldimethylsilyloxy)-9,10-secoergosta-5(E),7(E),10⁽¹⁹⁾,22(E)-tetraene 

Relevant academic research and scientific papers

Development of an improved process for doxercalciferol via a continuous photochemical reaction

Doxercalciferol (1α-hydroxyvitamin D2) is a commercially approved vitamin D derivative used to treat chronic kidney disease (CKD) patients whose kidneys cannot metabolically introduce a hydroxyl group at C1. A new process for the production of doxercalcif

Synthesis of 24(28)-methylene-1α-hydroxyvitamin D3, a novel vitamin D3 analogue

24(28)-Methylene-1α-hydroxyvitamin D3 was synthesised in 13 steps from vitamin D2. The key step of the synthesis involved the Wittig-Horner olefination of a nor-vitamin D2 aldehyde with diethylphosphono-3-methyl-2-butanone

Improved and efficient synthesis of Maxacalcitol

Maxacalcitol, the 22-oxa-derivative of 1α, 25-dihydroxyvitamin D 3, has been used as an antihyperparathyroidism and antipsoriatic drug. In this paper, an alternative synthetic route has been developed using commercially available vitamin D

Probing the structural requirements for vitamin D3 inhibition of the hedgehog signaling pathway

A structure-activity relationship study to elucidate the structural basis for hedgehog (Hh) signaling inhibition by vitamin D3 (VD3) was performed. Functional and non-functional regions of VD3 and VD2 were obtained through straightforward synthetic means

SYNTHESIS OF 1α-FLUORO-25-HYDROXY-16-23E-DIENE-26,27-BISHOMO-20-EPI-CHOLECALCIFEROL

The invention provides a method of producing 20-methyl vitamin D3 compounds of formula (I). The method includes hydroxylation, carbonyl reduction, fluoride substitution, epoxide deoxygenation, and Wittig-type couplings.

Method for preparing analogue of vitamin D

A method for preparing analogues of C1,C24-dihydroxy-vitamin D is disclosed. Especially the method for preparing calcipotriol and tacalcitol from a starting material of Vitamin D2 is disclosed here. Calcipotriol (compound 1(a)) and tacalcitol (compound 1(b)) can be synthesized by the method of the present invention. Moreover, only nine steps are needed for the synthesis of calcipotriol using the method. Likewise, only ten steps are needed for the synthesis of tacalcitol by the present method. Hence, the present method, with less process steps and higher yields, represents an improvement over the conventional methods.

Synthesis of a Biologically Active Vitamine-D2 Metabolite

The synthesis of 1α,25,28-trihydroxyvitamin-D2 (1) from vitamin-D2 is described.Approaches to the upper side-chain synthon via the chiral sulfone 15, prepared either through the enzymatic resolution of 10 or the opening of the optica

Hydrotitanation-Protonation of Vitamin D2 and Its Analogues: An Efficient Method for the Preparation of 10,19-Dihydrovitamins D2 Including Dihydrotachysterol2

In this study we describe an easy and efficient method for the preparation of the known 10,19-dihydrovitamins D2 2b (DHV2-II), 2c (DHV2-IV), 3c (dihydrotachysterol2, DHT2), and the new dihydrovitamins D2 2f and 2g.This method is based on the regioselective hydrometalation reaction of vitamin D2 and its derivatives with the system Cp2TiCl2-LiAlH4 or Cp2TiCl2-Red-Al (Aldrich).Under optimal conditions, the reaction with the former of these hydrometalating systems takes place with a high degree of stereoselectivity and allows labelling at C-19.